DekaBank Deutsche Girozentrale cut its stake in Alkermes PLC (NASDAQ:ALKS) by 0.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 96,571 shares of the company’s stock after selling 415 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Alkermes PLC were worth $5,633,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in ALKS. First Trust Advisors LP increased its position in shares of Alkermes PLC by 37.6% in the second quarter. First Trust Advisors LP now owns 979,813 shares of the company’s stock valued at $56,800,000 after buying an additional 267,742 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its position in Alkermes PLC by 1.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 448,804 shares of the company’s stock valued at $26,018,000 after buying an additional 6,484 shares during the period. Canada Pension Plan Investment Board boosted its position in Alkermes PLC by 20.2% in the second quarter. Canada Pension Plan Investment Board now owns 135,558 shares of the company’s stock valued at $7,858,000 after buying an additional 22,758 shares during the period. Kelly Lawrence W & Associates Inc. CA boosted its position in Alkermes PLC by 25.1% in the second quarter. Kelly Lawrence W & Associates Inc. CA now owns 118,100 shares of the company’s stock valued at $6,846,000 after buying an additional 23,700 shares during the period. Finally, IFP Advisors Inc boosted its position in Alkermes PLC by 10.9% in the second quarter. IFP Advisors Inc now owns 4,074 shares of the company’s stock valued at $236,000 after buying an additional 402 shares during the period. 97.19% of the stock is currently owned by institutional investors and hedge funds.

Alkermes PLC (NASDAQ ALKS) opened at 51.60 on Wednesday. Alkermes PLC has a one year low of $41.93 and a one year high of $63.40. The stock has a 50 day moving average of $56.35 and a 200 day moving average of $57.24. The firm’s market cap is $7.93 billion.

Alkermes PLC (NASDAQ:ALKS) last announced its earnings results on Thursday, July 27th. The company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.02. Alkermes PLC had a negative net margin of 24.33% and a negative return on equity of 9.12%. The business had revenue of $218.80 million during the quarter, compared to the consensus estimate of $216.54 million. During the same quarter last year, the firm earned ($0.01) earnings per share. Alkermes PLC’s quarterly revenue was up 12.1% on a year-over-year basis. Equities research analysts predict that Alkermes PLC will post ($0.04) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Alkermes PLC (ALKS) Stake Decreased by DekaBank Deutsche Girozentrale” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/08/16/alkermes-plc-alks-stake-decreased-by-dekabank-deutsche-girozentrale.html.

Several research firms recently weighed in on ALKS. J P Morgan Chase & Co set a $78.00 price objective on shares of Alkermes PLC and gave the stock a “buy” rating in a research report on Saturday, July 1st. BidaskClub cut shares of Alkermes PLC from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 9th. ValuEngine cut shares of Alkermes PLC from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. Morgan Stanley restated an “equal weight” rating and issued a $62.00 price objective on shares of Alkermes PLC in a research report on Monday, April 24th. Finally, Zacks Investment Research upgraded shares of Alkermes PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, August 2nd. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $63.00.

In other Alkermes PLC news, Director Paul J. Mitchell sold 1,500 shares of Alkermes PLC stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $57.49, for a total value of $86,235.00. Following the completion of the sale, the director now directly owns 9,500 shares of the company’s stock, valued at $546,155. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Shane Cooke sold 10,000 shares of Alkermes PLC stock in a transaction on Thursday, June 8th. The shares were sold at an average price of $60.33, for a total transaction of $603,300.00. Following the completion of the sale, the insider now directly owns 84,708 shares of the company’s stock, valued at $5,110,433.64. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 49,500 shares of company stock valued at $2,866,865. Insiders own 5.34% of the company’s stock.

Alkermes PLC Company Profile

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes PLC (NASDAQ:ALKS).

Institutional Ownership by Quarter for Alkermes PLC (NASDAQ:ALKS)

Receive News & Stock Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related stocks with our FREE daily email newsletter.